Clinical Trial Update: Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder [Phase 3]

View source ↗

Summary

An open-label Phase 3 safety study of solriamfetol for binge eating disorder is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• Solriamfetol (solriamfetol)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Binge-Eating Disorder | Phase 3 | Status: ENROLLING_BY_INVITATION